全文获取类型
收费全文 | 5789篇 |
免费 | 547篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 246篇 |
妇产科学 | 128篇 |
基础医学 | 789篇 |
口腔科学 | 81篇 |
临床医学 | 668篇 |
内科学 | 1210篇 |
皮肤病学 | 66篇 |
神经病学 | 561篇 |
特种医学 | 237篇 |
外科学 | 803篇 |
综合类 | 103篇 |
一般理论 | 1篇 |
预防医学 | 521篇 |
眼科学 | 371篇 |
药学 | 359篇 |
中国医学 | 2篇 |
肿瘤学 | 181篇 |
出版年
2022年 | 38篇 |
2021年 | 63篇 |
2020年 | 43篇 |
2019年 | 83篇 |
2018年 | 83篇 |
2017年 | 64篇 |
2016年 | 66篇 |
2015年 | 91篇 |
2014年 | 130篇 |
2013年 | 217篇 |
2012年 | 285篇 |
2011年 | 308篇 |
2010年 | 187篇 |
2009年 | 179篇 |
2008年 | 294篇 |
2007年 | 330篇 |
2006年 | 318篇 |
2005年 | 344篇 |
2004年 | 313篇 |
2003年 | 328篇 |
2002年 | 265篇 |
2001年 | 133篇 |
2000年 | 125篇 |
1999年 | 120篇 |
1998年 | 104篇 |
1997年 | 94篇 |
1996年 | 73篇 |
1995年 | 81篇 |
1994年 | 71篇 |
1993年 | 64篇 |
1992年 | 95篇 |
1991年 | 84篇 |
1990年 | 67篇 |
1989年 | 95篇 |
1988年 | 91篇 |
1987年 | 94篇 |
1986年 | 71篇 |
1985年 | 89篇 |
1984年 | 42篇 |
1983年 | 45篇 |
1981年 | 32篇 |
1980年 | 34篇 |
1979年 | 44篇 |
1978年 | 55篇 |
1977年 | 51篇 |
1976年 | 35篇 |
1975年 | 44篇 |
1974年 | 40篇 |
1973年 | 38篇 |
1972年 | 35篇 |
排序方式: 共有6346条查询结果,搜索用时 0 毫秒
92.
Megumi Oshima Meg J. Jardine Rajiv Agarwal George Bakris Christopher P. Cannon David M. Charytan Dick de Zeeuw Robert Edwards Tom Greene Adeera Levin Soo Kun Lim Kenneth W. Mahaffey Bruce Neal Carol Pollock Norman Rosenthal David C. Wheeler Hong Zhang Bernard Zinman Hiddo J.L. Heerspink 《Kidney international》2021,99(4):999-1009
93.
Jelena P. Seferovic Marc A. Pfeffer Brian Claggett Akshay S. Desai Dick de Zeeuw Steven M. Haffner John J. V. McMurray Hans-Henrik Parving Scott D. Solomon Nish Chaturvedi 《Diabetologia》2018,61(3):581-588
Aims/hypothesis
The self-administered Michigan Neuropathy Screening Instrument (MNSI) is used to diagnose diabetic peripheral neuropathy. We examined whether the MNSI might also provide information on risk of death and cardiovascular outcomes.Methods
In this post hoc analysis of the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) trial, we divided 8463 participants with type 2 diabetes and chronic kidney disease (CKD) and/or cardiovascular disease (CVD) into independent training (n = 3252) and validation (n = 5211) sets. In the training set, we identified specific questions that were independently associated with a cardiovascular composite outcome (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction/stroke, heart failure hospitalisation). We then evaluated the performance of these questions in the validation set.Results
In the training set, three questions (‘Are your legs numb?’, ‘Have you ever had an open sore on your foot?’ and ‘Do your legs hurt when you walk?’) were significantly associated with the cardiovascular composite outcome. In the validation set, after multivariable adjustment for key covariates, one or more positive responses (n = 3079, 59.1%) was associated with a higher risk of the cardiovascular composite outcome (HR 1.54 [95% CI 1.28, 1.85], p < 0.001), heart failure hospitalisation (HR 1.74 [95% CI 1.29, 2.35], p < 0.001), myocardial infarction (HR 1.81 [95% CI 1.23, 2.69], p = 0.003), stroke (HR 1.75 [95% CI 1.20, 2.56], p = 0.003) and three-point major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) (HR 1.49 [95% CI 1.20, 1.85], p < 0.001) relative to no positive responses to all questions. Associations were stronger if participants answered positively to all three questions (n = 552, 11%). The addition of the total number of affirmative responses to existing models significantly improved Harrell’s C statistic for the cardiovascular composite outcome (0.70 vs 0.71, p = 0.010), continuous net reclassification improvement (+22% [+10%, +31%], p = 0.027) and integrated discrimination improvement (+0.9% [+0.4%, +2.1%], p = 0.007).Conclusions/interpretation
We identified three questions from the MNSI that provide additional prognostic information for individuals with type 2 diabetes and CKD and/or CVD. If externally validated, these questions may be integrated into the clinical history to augment prediction of CV events in high-risk individuals with type 2 diabetes.94.
Strauss BH Segev A Wright GA Qiang B Munce N Anderson KJ Leung G Dick AJ Virmani R Butany J 《Journal of interventional cardiology》2005,18(6):425-436
Arterial chronic total occlusions (CTO) are a common and clinically relevant problem in patients with coronary artery disease. Percutaneous coronary intervention (PCI) success rates in a wide range of CTO are low, primarily due to inability of guidewire crossing. The pathophysiology of CTO is poorly understood and limits our ability to introduce innovative therapies. Recent studies from our laboratory have suggested that microvessel formation within arterial CTO is a complex process with temporal and regional differences. Moreover, there is evidence from pilot studies that the presence of either microvessels or the particular extracellular matrix environment in the adjacent perivascular tissue can facilitate guidewire crossing and successful PCI. Currently, studies are underway in our experimental CTO model to delineate the pathophysiology of microvessel formation in CTO and its potential role in PCI. 相似文献
95.
Anindita Chakraborty Jing Pang Dick C. Chan Wendy Barnett Ann Marie Woodward Mary Vorster Gerald F. Watts 《Clinical cardiology》2021,44(6):805
BackgroundLipoprotein(a) (Lp[a]) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin‐9 monoclonal antibodies (PCSK9mAbs) can lower Lp(a) levels in clinical trials, but their effects in patients with elevated Lp(a) in clinical practice remain unclear.AimsTo investigate the effectiveness and safety of PCSK9mAbs in lowering plasma Lp(a) in patients with elevated Lp(a) concentrations in a lipid clinic.MethodsThis was an open‐label study of 53 adult patients with elevated Lp(a) concentration (≥0.5 g/L). Clinical, biochemical, and safety data were collected before and on treatment with evolocumab or alirocumab over a mean period of 11 months.ResultsTreatment with a PCSK9mAb resulted in a significant reduction of 0.29 g/L (−22%) in plasma Lp(a) concentration (p<.001). There were also significant reductions in low‐density lipoprotein‐cholesterol (LDL‐C) (−53%), remnant‐cholesterol (−12%) and apolipoprotein B (−43%) concentrations. The change in Lp(a) concentration was significantly different from a comparable group of 35 patients with elevated Lp(a) who were not treated with a PCSK9mAb (−22% vs. −2%, p<.001). The reduction in Lp(a) concentration was not associated with the corresponding changes in LDL‐C, remnant‐cholesterol, and apolipoprotein B (p>.05 in all). 7.5% and 47% of the patients attained a target concentration of Lp(a) <0.5 g/L and LDL‐C <1.8 mmol/L, respectively. PCSK9mAbs were well tolerated, the common adverse effects being pharyngitis (9.4%), nasal congestion (7.6%), myalgia (9.4%), diarrhoea (7.6%), arthralgia (9.4%) and injection site reactions (11%).ConclusionPCSK9mAbs can effectively and safely lower plasma Lp(a) concentrations in patients with elevated Lp(a) in clinical practice; the impact of the fall in Lp(a) on ASCVD outcomes requires further investigation. 相似文献
96.
97.
Yamashita T; Wu N; Kupfer G; Corless C; Joenje H; Grompe M; D'Andrea AD 《Blood》1996,87(10):4424-4432
Fanconi anemia (FA) is an autosomal recessive disease characterized by congenital anomalies, aplastic anemia, and cancer susceptibility. Mutations within the FA complementation group C (FAC) gene account for approximately 14% of diagnosed FA cases. Two mutations, one in exon 1 (delG322) and one in exon 4 (IVS4 + 4 A to T), account for 90% of known FAC mutations. The delG322 mutation results in a mild FA phenotype, while the IVS4 + 4 A to T mutation results in severe FA phenotype. To determine the molecular basis for this clinical variability, we analyzed patient-derived cell lines for the expression of characteristic mutant FAC polypeptides. All cell lines with the delG322 mutation expressed a 50-kD FAC polypeptides, FRP-50 (FAC-related protein), shown to be an amino terminal truncated isoform of FAC reinitiated at methionine 55. All cell lines with the IVS4 + 4 A to T mutation lacked FRP-50. Overexpression of a cDNA encoding FRP-50 in an FA(C) cell line resulted in partial correction of mitomycin C sensitivity. In conclusion, expression of an amino terminal truncated FAC protein accounts, at least in part, for the clinical heterogeneity among FA(C) patients. 相似文献
98.
Venigalla RK Tretter T Krienke S Max R Eckstein V Blank N Fiehn C Ho AD Lorenz HM 《Arthritis and rheumatism》2008,58(7):2120-2130
OBJECTIVE: CD4+,CD25high regulatory T (Treg) cells play a crucial role in the maintenance of self tolerance and prevention of organ-specific autoimmunity. The presence of many in vivo-preactivated CD4+,CD25++ T cells in patients with systemic lupus erythematosus (SLE) poses a difficulty in discriminating CD25++ activated T cells from CD25high Treg cells. To overcome this problem, we analyzed the phenotype and function of CD4+,CD25high,CD127(-/low) natural Treg (nTreg) cells isolated from the peripheral blood of patients with SLE. METHODS: CD4+,CD25high,CD127(-/low) nTreg cells and CD4+,CD25- responder T (Tresp) cells from patients with SLE and normal donors were separated by fluorescence-activated cell sorting. Cell proliferation was quantified by 3H-thymidine incorporation, and immunophenotyping of the cells was done using FACScan. RESULTS: Comparable percentages of CD4+,CD25high,FoxP3+ T cells were observed in patients with SLE and normal donors. Proliferation of SLE nTreg cells sorted into the subset CD4+,CD25high,CD127(-/low) was significantly decreased compared with that of SLE nTreg cells sorted into the subset CD4+,CD25high (mean +/- SEM 2,223 +/- 351 counts per minute versus 9,104 +/- 1,720 cpm, respectively), while in normal donors, these values were 802 +/- 177 cpm and 2,028 +/- 548 cpm, respectively, confirming that effector cell contamination was reduced. Notably, the suppressive activity of nTreg cells was intact in all groups. However, CD4+,CD25- Tresp cells isolated from patients with active SLE were significantly less sensitive than those from patients with inactive SLE to the suppressive function of autologous or normal donor CD4+,CD25high,CD127(-/low) nTreg cells. Furthermore, a significant inverse correlation was observed between the extent of T cell regulation in suppressor assays and the level of lupus disease activity. CONCLUSION: This study is the first to show that, in human SLE, impaired sensitivity of Tresp cells to the suppressive effects of a comparably functional, highly purified nTreg cell population leads to a defective suppression of T cell proliferation in active SLE. Studies aiming to define the mechanisms leading to Tresp cell resistance might help in the development of highly specific, alternative immunotherapeutic tools for the control of systemic autoimmune diseases such as SLE. 相似文献
99.
L. Daas N. Szentmáry T. Eppig A. Langenbucher A. Hasenfus M. Roth M. Saeger B. Nölle B. Lippmann D. Böhringer T. Reinhard C. Kelbsch E. Messmer U. Pleyer S. Roters A. Zhivov K. Engelmann J. Schrecker L. Zumhagen H. Thieme R. Darawsha T. Meyer-ter-Vehn B. Dick I. Görsch M. Hermel M. Kohlhaas B. Seitz 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》2015,112(9):752-763